Title:
FUSION PROTEIN FOR TREATMENT OF METABOLIC DISEASE
Document Type and Number:
WIPO Patent Application WO/2020/228360
Kind Code:
A1
Abstract:
The present invention relates to the field of biotechnologies, and provides a fusion protein for treatment of a metabolic disease, and a preparation method therefor and use thereof. The fusion protein comprises a Glucagon analogue fragment and a long-acting protein unit fragment. The Glucagon analogue fragment comprises: a) a polypeptide fragment having the amino acid sequence as shown by SEQ ID No. 81; and b) a polypeptide fragment which has an amino acid sequence having more than 90% sequence identity with SEQ ID NO. 81 and has the function of the polypeptide fragment defined in a). The fusion protein provided by the present invention has good stability, and has good blood sugar reduction and weight loss effects for mice.
More Like This:
Inventors:
HUANG YANSHAN (CN)
Application Number:
PCT/CN2020/070234
Publication Date:
November 19, 2020
Filing Date:
January 03, 2020
Export Citation:
Assignee:
ZHEJIANG DOER BIOLOGICS CORP (CN)
International Classes:
C07K19/00; A61K38/26; A61P3/00; A61P3/04; C12N15/62; C12P21/00
Domestic Patent References:
| WO1999057151A2 | 1999-11-11 | |||
| WO2016114633A1 | 2016-07-21 |
Foreign References:
| CN109306015A | 2019-02-05 | |||
| CN107995914A | 2018-05-04 | |||
| US9018164B2 | 2015-04-28 | |||
| US9150632B2 | 2015-10-06 | |||
| US20140213512A1 | 2014-07-31 | |||
| US8188040B2 | 2012-05-29 | |||
| US9493530B2 | 2016-11-15 | |||
| US20150291677A1 | 2015-10-15 | |||
| US9422353B2 | 2016-08-23 | |||
| US8541369B2 | 2013-09-24 | |||
| US7622445B2 | 2009-11-24 | |||
| US7576190B2 | 2009-08-18 | |||
| US20070142278A1 | 2007-06-21 | |||
| US9006400B2 | 2015-04-14 | |||
| US20130252884A1 | 2013-09-26 |
Other References:
N ENGL J MED, vol. 355, no. 23, 2006, pages 2427 - 43
SCAND J CLIN LAB INVEST, vol. 75, no. 2, 2015, pages 121 - 5
NATURE MEDICINE, vol. 22, no. 7, 2016, pages 694 - 695
MATTHIAS H. TSCHOP ET AL., CELL METAB, vol. 24, no. 1, 2016, pages 51 - 62
ALESSANDRO POCAI ET AL.: "reported a GLP-1R/GCGR dual agonist based on Oxyntomodulin (OXM", DIABETES, vol. 58, no. 10, 2009, pages 2258 - 2266
RICHARD D. DIMARCHI ET AL., REPORTED A GCG-BASED GLP-1R/GCGR DUAL AGONIST
DIABETES CARE, vol. 36, 2013, pages 498 - 504
DIABETES OBESMETAB, vol. 18, no. 12, 2016, pages 1176 - 1190
PROC NATL ACADSCI USA, vol. 109, no. 8, 2012, pages 3143 - 8
MOLMETAB, vol. 5, no. 8, 2016, pages 690 - 8
J INTERN MED, vol. 281, no. 3, 2017, pages 233 - 246
LANCET, vol. 368, 2006, pages 1696 - 705
TRENDS PHARMACOLSCI, vol. 32, no. 1, 2011, pages 8 - 15
BIOORG MED CHEM LETT, vol. 23, no. 14, 2013, pages 4011 - 8
EXPERT OPINLNVESTIG DRUGS, vol. 25, no. 2, 2016, pages 145 - 58
NAT. REV. ENDOCRINOL, vol. 6, 2010, pages 689 - 697
"Sequences of proteins of immunological interest", 1991, NATIONAL INSTITUTES OF HEALTH
JOSEPH R. CHABENNE ET AL., J DIABETES SCI TECHNOL., vol. 4, no. 6, 2010, pages 1322 - 1331
EVERS A ET AL., J MED CHEM., vol. 60, no. 10, 2017, pages 4293 - 4303
J. PEPT. SCI., vol. 14, 2008, pages 588 - 595
CELL METABOLISM, vol. 24, 2016, pages 51 - 62
LTEIF, MATHER, CAN. J. CARDIOL., vol. 20, 2004, pages 66B - 76B
SAMBROOK ET AL.: "MOLECULAR CLONING: A LABORATORY MANUAL", 1989, COLD SPRING HARBOR LABORATORY PRESS
AUSUBEL ET AL.: "CURRENT PROTOCOLS IN MOLECULAR BIOLOGY", 1987, JOHN WILEY & SONS
WOLFFE: "CHROMATIN STRUCTURE AND FUNCTION", 1998, ACADEMIC PRESS
"METHODS IN MOLECULAR BIOLOGY", vol. 119, 1999, ACADEMIC PRESS, article "Chromatin Protocols"
XU J ET AL., BIOCONJUG CHEM., vol. 24, no. 6, 2013, pages 915 - 25
See also references of EP 3971214A4
SCAND J CLIN LAB INVEST, vol. 75, no. 2, 2015, pages 121 - 5
NATURE MEDICINE, vol. 22, no. 7, 2016, pages 694 - 695
MATTHIAS H. TSCHOP ET AL., CELL METAB, vol. 24, no. 1, 2016, pages 51 - 62
ALESSANDRO POCAI ET AL.: "reported a GLP-1R/GCGR dual agonist based on Oxyntomodulin (OXM", DIABETES, vol. 58, no. 10, 2009, pages 2258 - 2266
RICHARD D. DIMARCHI ET AL., REPORTED A GCG-BASED GLP-1R/GCGR DUAL AGONIST
DIABETES CARE, vol. 36, 2013, pages 498 - 504
DIABETES OBESMETAB, vol. 18, no. 12, 2016, pages 1176 - 1190
PROC NATL ACADSCI USA, vol. 109, no. 8, 2012, pages 3143 - 8
MOLMETAB, vol. 5, no. 8, 2016, pages 690 - 8
J INTERN MED, vol. 281, no. 3, 2017, pages 233 - 246
LANCET, vol. 368, 2006, pages 1696 - 705
TRENDS PHARMACOLSCI, vol. 32, no. 1, 2011, pages 8 - 15
BIOORG MED CHEM LETT, vol. 23, no. 14, 2013, pages 4011 - 8
EXPERT OPINLNVESTIG DRUGS, vol. 25, no. 2, 2016, pages 145 - 58
NAT. REV. ENDOCRINOL, vol. 6, 2010, pages 689 - 697
"Sequences of proteins of immunological interest", 1991, NATIONAL INSTITUTES OF HEALTH
JOSEPH R. CHABENNE ET AL., J DIABETES SCI TECHNOL., vol. 4, no. 6, 2010, pages 1322 - 1331
EVERS A ET AL., J MED CHEM., vol. 60, no. 10, 2017, pages 4293 - 4303
J. PEPT. SCI., vol. 14, 2008, pages 588 - 595
CELL METABOLISM, vol. 24, 2016, pages 51 - 62
LTEIF, MATHER, CAN. J. CARDIOL., vol. 20, 2004, pages 66B - 76B
SAMBROOK ET AL.: "MOLECULAR CLONING: A LABORATORY MANUAL", 1989, COLD SPRING HARBOR LABORATORY PRESS
AUSUBEL ET AL.: "CURRENT PROTOCOLS IN MOLECULAR BIOLOGY", 1987, JOHN WILEY & SONS
WOLFFE: "CHROMATIN STRUCTURE AND FUNCTION", 1998, ACADEMIC PRESS
"METHODS IN MOLECULAR BIOLOGY", vol. 119, 1999, ACADEMIC PRESS, article "Chromatin Protocols"
XU J ET AL., BIOCONJUG CHEM., vol. 24, no. 6, 2013, pages 915 - 25
See also references of EP 3971214A4
Attorney, Agent or Firm:
J.Z.M.C. PATENT AND TRADEMARK LAW OFFICE (GENERAL PARTNERSHIP) (CN)
Download PDF: